^
    Back
    Association details:
    Biomarker:HER-2 mutation
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Margenza (margetuximab-cmkb) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Title:

    Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

    Excerpt:
    Unresectable locally advanced or metastatic histologically proven HER2+ gastroesophageal junction (GEJ) or gastric cancer. Gastric Cancer Expansion Phase will include only gastric cancer patients with 3+ HER2 positivity...Have received prior treatment with trastuzumab.
    Trial ID:
    NCT02689284
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2018
    Title:

    BIOMARKER-GUIDED ENRICHMENT OF THE ANTITUMOR ACTIVITY OF MARGETUXIMAB (M) PLUS PEMBROLIZUMAB (P) IN PATIENTS WITH ADVANCED HER2+ GASTRIC ADENOCARCINOMA (GEA)

    Published date:
    10/21/2018
    Excerpt:
    The presence of ERBB2 amplification by ctDNA and tumor PD-L1 expression by IHC were both associated with increased probability of OR: 33.3% v. 10.5% (p = 0.0948) and 43.8% v. 16.7% (p = 0.0769), respectively. ORR was 5 of 8 (62.5%) in ERBB2 amplified/PD-L1+ pts. In pts with activating HER2 mutations DCR was 11/15 (73%), indicating ADCC.
    DOI:
    10.1093/annonc/mdy282
    Trial ID:
    NCT02689284